Login to Your Account

Financings Roundup

Friday, March 29, 2013

• ARCA Biopharma Inc., of Broomfield, Co., filed for a public offering of $20 million in stock and warrants to fund the Phase IIb portion of the GENETIC-AF trial of Gencaro (bucindolol hydrochloride) for atrial fibrillation. Dawson James Securities Inc. is the lead placement agent.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription